Precision over presence: Why personalization at scale drives better patient engagement

Commercial Strategy Optimization Oncology & Hematology Launch Post-launch
Gosia Leitch
VP of Engagement Solutions
Engagement Solutions
Connect
hcp insight moment pair

In today's competitive market, pharma marketers need to move beyond broad awareness campaigns. Instead they need to deliver timely, personalized engagement that influences prescribing decisions. Dynamic audience segmentation and real-time execution are still a struggle for many teams. That's despite having access to mature digital channels. The result? Missed opportunities, fragmented messaging, and underwhelming impact.

Personalization at scale is no longer optional, it’s the key to commercial success. As precision medicine evolves, marketers need to tailor outreach to each HCP's needs and behaviour. DXRX Physician Engage delivers precision targeting and personalized messaging at scale. This helps marketers connect with the right HCPs at the right moment, This helps marketers connect with the right HCPs at the right moment, improving patient engagement.

The execution gap: Why timely outreach still eludes marketers

Only a minority of companies are using real-time clinical or behavioral triggers to inform outreach (Veeva Pulse, 2023). That's despite 88% citing a high level of interest in analytics and AI to optimize HCP targeting (Digital Health Coalition, 2025). Many teams have the ambition, but lack the tools and processes needed for effective HCP engagement.

Marketers often have access to the right channels but lack the infrastructure to act on real-time data. Without dynamic segmentation and timely activation, even well-crafted campaigns risk falling flat.

At Johns Hopkins Medicine, AI tools are helping physicians work more efficiently. These tools combine clinical data to help physicians make better decisions and spend more time on patient care (Johns Hopkins Medicine, 2025). This underscores the urgency of enabling smarter, data-driven engagement. The goal is to help physicians make timely, informed decisions. By delivering relevant outreach within 24 hours of key diagnostic events. This helps improve patient outcomes and commercial impact, and patient engagement.

From multi-modal AI-driven data to strategy: Building smarter patient engagement flows

Scalable personalization requires more than just data, it demands orchestration. Effective engagement flows are built on three pillars:

  • Advanced segmentation: Beyond basic demographics. Including prescribing behavior, diagnostic triggers, and digital preferences.
  • Multimodal AI-driven data: Combining lab, genomic, claims and EHR data. Provide real-time insights that enable engagement at key moments.
  • Consistent messaging: Aligning digital, content, and field teams. Deliver unified, relevant communications across every touchpoint.

Diaceutics has found that targeted campaigns combining real-time data, digital content and peer-to-peer education can increase new prescriptions by 35.6% (Diaceutics Webinar, 2025). Delivering tailored, timely messages to physicians increases the chance of behaviour change.

Internal alignment: The hidden driver of personalization success

Technology alone doesn’t drive personalization, teams do. Many pharma teams still have a disconnect between digital, content and field teams. This leads to a lack of personalization and inconsistent messaging. Which in turn results in slower adoption and missed opportunities to reach eligible patients.

Diaceutics helps bridge these gaps. Diaceutics uses AI and real-world data to help pharma marketers reach the right HCPs at the right time. Our solutions connect digital and field teams to deliver when it matters most. This creates better opportunities for patient engagement. Physicians are notified within 24 hours of diagnosis and in the moments before vital decisions are made.

Looking ahead: Turning potential into performance

Personalization at scale isn’t just a buzzword, it’s a commercial imperative. In a recent survey, 85% of pharma leaders described AI as an “immediate priority” (Fierce Pharma, 2025). Diaceutics empowers marketing teams to produce proactive influence strategies. AI, real-time HCP and patient data work together to improve commercial outcomes and patient engagement.

Let’s talk

If your team is ready to move from fragmented outreach to precise real-time engagement, Diaceutics can help. Contact Diaceutics today to discover our data-driven solutions. Improve HCP targeting, strengthen patient engagement, and deliver better commercial outcomes.

About Diaceutics

We’ve been with pharma and biotech companies for over 20 years, helping them to make more informed diagnostic and therapeutic decisions based on real-world data. Our platforms and tools provide global insight from a network of laboratories across 50+ countries.

This unparalleled visibility into real-world testing helps support therapy programs across oncology, cardiology, neurology, autoimmune, rare diseases, and many more.

Contact us
Written By Gosia Leitch
Leading our Engagement Solutions, Gosia designs and delivers data-driven HCP engagement strategies that help pharma partners unlock the full potential of diagnostically driven therapies and accelerate biomarker and treatment adoption. Since joining Diaceutics in 2024, Gosia has been pivotal in scaling Engagement Solutions, sharpening our commercial proposition and driving deeper utilisation of genomics and oncology diagnostics across global pharma accounts. With 20+ years in diagnostics and pharma, including senior roles at Veracyte, Abbott and Bayer, Gosia brings expertise in commercial strategy, brand management and HCP education. She holds an MBA from the University of Iowa and executive education in Corporate Strategy from Columbia Business School.
Read more by this author

FAQs

What is personalisation at scale in pharmaceutical marketing?
Personalisation at scale is the ability to deliver relevant, tailored content and engagement to healthcare professionals (HCPs) based on their behaviour, interests, prescribing patterns, and patient needs. By combining AI, real-world data, and advanced segmentation, pharmaceutical companies can engage the right HCP with the right message at the right time, improving both patient engagement and commercial outcomes.
Why is personalised HCP engagement important for patient outcomes?
Personalised HCP engagement helps physicians access relevant information when critical treatment decisions are being made. Timely, data-driven outreach can increase awareness of appropriate therapies, support informed prescribing decisions, and help identify eligible patients faster. This can ultimately lead to improved patient engagement and better health outcomes.
How can AI improve patient engagement strategies in pharma?
AI enables pharmaceutical companies to analyse large volumes of clinical, behavioural, and healthcare data in real time. This allows marketers to identify engagement opportunities, create dynamic audience segments, and trigger relevant communications based on diagnostic or prescribing events. The result is more precise outreach that supports both physician decision-making and patient engagement.
What data sources support personalised pharmaceutical marketing?
Effective personalised marketing strategies often combine multiple data sources, including laboratory data, genomic data, claims data, electronic health records (EHRs), prescribing behaviour, and digital engagement signals. Bringing these datasets together provides a more complete view of HCP needs and enables more relevant engagement at scale.
What are the biggest barriers to personalisation at scale?
Many pharmaceutical organisations struggle with fragmented data, siloed teams, static audience segmentation, and limited ability to activate insights in real time. Without strong alignment between digital, content, and field teams, marketers may miss opportunities to deliver timely and relevant communications that drive physician action and patient engagement.
How does real-time HCP targeting improve commercial performance?
Real-time HCP targeting allows marketers to engage physicians shortly after key clinical events occur, such as a diagnosis or treatment consideration. By delivering relevant information when HCPs are actively evaluating therapeutic options, pharmaceutical companies can increase engagement, support prescribing decisions, improve patient identification, and drive stronger commercial results.
References

  1. Veeva Pulse Field Trends Report, 2023.

  2. Digital Health Coalition, 2025. Predicting 2025 Trends.
  3. Johns Hopkins Medicine, 2025, August 20. New Method Advances Reliability of AI with Applications in Medical Diagnostics.
  4. Diaceutics Webinar: Transforming Physician Identification lp.diaceutics.com/webinar-2025-24-june-catch-up/
  5. Stanford Institute for Human-Centered AI, 2024. AI Index Annual Report.
  6. Stanford Institute for Human-Centered AI, 2024. AI Index Annual Report.
  7. Fierce Pharma, 2025, July 10. Strategic Use of AI in Healthcare and Pharma Drives Market Advantage.
Commercial Strategy Optimization Oncology & Hematology Launch Post-launch
Share:

Newsletter sign up

Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.

READY TO DO COMMERCIALIZATION DIFFERENTLY?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.